TP53 and cancer: Mechanistic research showed that TRIB1 enhanced HDAC1-mediated p53 deacetylation, decreased p53 binding to DNA, and reduced p53 tumor suppressor activity, suggesting that TRIB1 may be a new molecular target for cancer treatment 53 (Table 2).